Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.
In spite of market turmoil, this year has been bright so far for AbbVie (NYSE: ABBV). The company's star drug Humira continues to grow, and even reached the milestone of more than $20 billion in sales last year. Its other immunology drugs and the neuroscience business also are thriving.
Prolonged periods of volatility along with dips near or even into bear market territory have become commonplace for investors in recent months as fears of a looming recession, geopolitical headwinds, and ongoing concerns about the global economy continue to remain front of mind. For investors who have the capital to put to work right now, even a market like the one we're seeing presents its own share of opportunities to invest in these types of compelling companies at a bargain. Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in this space.